Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

Laure Vincent, Anne Charvet-Rumpler, Lotfi Benboubker, Claire Calmettes, Anne-Marie Stoppa, Kamel Laribi, Lauriane Clement Filliatre, Fressia Honeyman, Richez Valentine, Cyrille Hulin, Frédéric Maloisel, Margaret Macro, Lionel Karlin, Vanessa Barué, Christos Chouaid, Hacène Zerazhi, Xavier Leleu

Blood (2022) 140 (Supplement 1): 4312–4314.

https://doi.org/10.1182/blood-2022-157942

Published: 2022

Journal Articles

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Blood (2022) 140 (Supplement 1): 4379–4381.

https://doi.org/10.1182/blood-2022-158484

Published: 2022

Journal Articles

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

Lauriane Clement-Filliatre, MD, Lotfi Benboubker, MD, Anne-Marie Stoppa, Philippe Rodon, MD, Kamel Laribi, MD, Laure Vincent, Philippe Collet, Valentine Richez, MD, Anne Charvet-Rumpler, Hacene Zerazhi, MD, Cyrille Hulin, MD, Frederic Maloisel, MD PhD, Margaret Macro, Lionel Karlin, MD, Nathalie Texier, Christos Chouaid, Xavier Leleu, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-133807

Published: 2020

Journal Articles

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Xavier Troussard, MD, Laure Montané, Mourad Tiab, Carine Chaleteix, MD, Isabelle Grulois, Clothilde Lindet, Delphine Legoupil, Frederic Kohser, Diane Pannier, Frederic Maloisel, Pierre Bories, Céline AIT Oukhatar, Natalie Hoog Labouret, Jean-Yves Blay, MD PhD

Blood (2017) 130 (Supplement 1): 156.

https://doi.org/10.1182/blood.V130.Suppl_1.156.156

Published: 2017

Journal Articles

Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS

Blood (2017) 130 (Supplement 1): 1705.

https://doi.org/10.1182/blood.V130.Suppl_1.1705.1705

Published: 2017

Journal Articles

Good Usage of Biosimilar Filgrastim: A Subanalysis of the Next Study

Stephane Leprêtre, Frédéric Maloisel, Didier Kamioner, Christian Berthou, Hélène Albrand

Blood (2014) 124 (21): 4974.

https://doi.org/10.1182/blood.V124.21.4974.4974

Published: 2014

Journal Articles

Safety of Biosimilar Filgrastim in Patients Undergoing Neutropenia-Inducing Chemotherapy: The Next Study

Stephane Leprêtre, Frédéric Maloisel, Didier Kamioner, Christian Berthou, Hélène Albrand

Blood (2014) 124 (21): 4976.

https://doi.org/10.1182/blood.V124.21.4976.4976

Published: 2014

Journal Articles

Safety of Biosimilar Filgrastim in Patients with Haematological Malignancies Undergoing Neutropenia-Inducing Chemotherapy: A Subanalysis of the Next Study

Stephane Leprêtre, Frédéric Maloisel, Didier Kamioner, Christian Berthou, Hélène Albrand

Blood (2014) 124 (21): 4977.

https://doi.org/10.1182/blood.V124.21.4977.4977

Published: 2014

Journal Articles

Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferonα2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la leucemie myéloïde chronique)

Francois Guilhot, Francoise Rigal-Huguet, MD, Joelle Guilhot, PhD, Agnès Guerci-Bresler, MD, Franck E. Nicolini, MD PhD, Frédéric Maloisel, Delphine Rea, MD PhD, Valerie Coiteux, MD, Martine Gardembas, MD, Anne Vekhoff, MD, Eric Jourdan, MD PhD, Laurence Legros, MD PhD, Martine Escoffre-Barbe, MD, Philippe Rousselot, MD, Claude Preudhomme, MD PhD, Francois-Xavier Mahon, MD PhD

Blood (2014) 124 (21): 1793.

https://doi.org/10.1182/blood.V124.21.1793.1793

Published: 2014

Journal Articles

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Blood (2014) 123 (26): 4136–4142.

https://doi.org/10.1182/blood-2013-12-546374

Published: 2014

Journal Articles

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Mathieu Leclerc, MD, Felipe Suarez, MD, PhD, Marie-Pierre Noël, MD, Anne Vekhoff, MD, Xavier Troussard, MD, Jean-François Claisse, MD, Catherine Thieblemont, MD, PhD, Frédéric Maloisel, MD, PhD, Yves Beguin, MD, PhD, Jérôme Tamburini, MD, PhD, Coralie Barbe, MD, Alain Delmer, MD

Blood (2013) 122 (21): 5308.

https://doi.org/10.1182/blood.V122.21.5308.5308

Published: 2013

Journal Articles

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC

Blood (2011) 117 (23): 6109–6119.

https://doi.org/10.1182/blood-2010-11-317073

Published: 2011

Journal Articles

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Blood (2009) 114 (22): 3293.

https://doi.org/10.1182/blood.V114.22.3293.3293

Published: 2009

Journal Articles

Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC).

François Guilhot, MD, Claude Preudhomme, Joelle Guilhot, MSci, Francois-Xavier Mahon, MD, PhD, Franck Emmanuel Nicolini, MD, PhD, Francoise Rigual-Huguet, MD, Laurence Legros, MD, PhD, Agnès Guerci, MD, PhD, Delphine Rea, MD, PhD, Valerie Coiteux, MD, Frederic Maloisel, MD, Martine Gardembas, MD, Claude-Eric Bulabois, MD, Marc G Berger, MD, PhD

Blood (2009) 114 (22): 340.

https://doi.org/10.1182/blood.V114.22.340.340

Published: 2009

Journal Articles

Autologous Stem Cell Transplantation (ASCT) in CLL. Results of a Phase III Randomized Multicenter Trial.

Blood (2009) 114 (22): 878.

https://doi.org/10.1182/blood.V114.22.878.878

Published: 2009

Journal Articles

Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL

Blood (2008) 112 (11): 139.

https://doi.org/10.1182/blood.V112.11.139.139

Published: 2008

Journal Articles

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Blood (2008) 112 (11): 183.

https://doi.org/10.1182/blood.V112.11.183.183

Published: 2008

Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Yeow Tee Goh, MD, Tamas Masszi, MD, PhD, Ricardo Pasquini, Frederic Maloisel, M. Brigid Bradley-Garelik, Chao Zhu, Herve Dombret, MD, PhD, FRCP

Blood (2008) 112 (11): 3226.

https://doi.org/10.1182/blood.V112.11.3226.3226

Published: 2008

Journal Articles

Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM)

Veronique Leblond, MD, Jerome Tamburini, MD, Vincent Levy, MD, PhD, Sylvain Choquet, MD, Anne Laure Taksin, MD, Frederic Maloisel, MD, Pierre Morel, MD

Blood (2007) 110 (11): 1291.

https://doi.org/10.1182/blood.V110.11.1291.1291

Published: 2007

Journal Articles

VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial.

Jean-Luc Harousseau, MD, Gerald Marit, MD, Denis Caillot, MD, Philippe Casassus, MD, Thierry Facon, MD, Mohamad Mohty, MD, PhD, Frederic Maloisel, MD, Herve Maisonneuve, MD, Carine Chaleteix, MD, Lofti Benboubker, MD, PhD, Dixie-Lee Esseltine, MD, Michel Attal, MD

Blood (2006) 108 (11): 56.

https://doi.org/10.1182/blood.V108.11.56.56

Published: 2006

NARROW

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS

Good Usage of Biosimilar Filgrastim: A Subanalysis of the Next Study

Safety of Biosimilar Filgrastim in Patients Undergoing Neutropenia-Inducing Chemotherapy: The Next Study

Safety of Biosimilar Filgrastim in Patients with Haematological Malignancies Undergoing Neutropenia-Inducing Chemotherapy: A Subanalysis of the Next Study

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Autologous Stem Cell Transplantation (ASCT) in CLL. Results of a Phase III Randomized Multicenter Trial.

Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035

Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM)

VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only